Riskpilot← Back to searchSign inGet full accessRINGEN APOTEK KLØFTA AS
ASActiveOrg 920362001Gjerdrumsvegen 5, 2040 KløftaRetail sale of pharmaceutical products · NACE 4773Est. 20182 employees
Revenue 2024
NOK 11,3M
+11% vs 2023
EBITDA margin
2.0%
+227% vs 2023
Equity ratio
14.6%
Financial strength
Net profit 2024
NOK 156K
+193% vs 2023
| Revenue | NOK 11,3M | +11% |
| EBITDA | NOK 228K | +227% |
| Net profit | NOK 156K | +193% |
| Total assets | NOK 2,4M | -11% |
| Equity | NOK 357K | -39% |
| Employees | 2 | — |
Legal name
RINGEN APOTEK KLØFTA AS
Org number
920362001
Legal form
Aksjeselskap
NACE code
4773 · Retail sale of pharmaceutical products
Founded
1. februar 2018
Share capital
NOK 30 000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets medlemmer hver for seg.
Company purpose
Eie og drive apotek, herunder konsulenttjenester innenfor apotekerbransjen og lege- og helserelaterte produkter, samt øvrig virksomhet i tilknytning til dette.
Address
Gjerdrumsvegen 5, 2040 Kløfta
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 8 421 | 9 601 | 9 856 | 10 175 | 11 269 |
| Staff expenses | −1 638 | −1 693 | −1 465 | −2 128 | −1 643 |
| EBITDA | 159 | 438 | 413 | −179 | 228 |
| Depreciation & amort. | −52 | −52 | −52 | −18 | −0 |
| EBIT | 106 | 385 | 360 | −197 | 228 |
| Net financials | −28 | −18 | −27 | −37 | −20 |
| Profit before tax | 78 | 367 | 333 | −234 | 208 |
| Tax | 20 | 81 | 74 | −66 | 52 |
| Net profit | 59 | 286 | 259 | −168 | 156 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1 991 | 2 168 | 3 163 | 2 749 | 2 445 |
| Equity | −22 | 265 | 524 | 588 | 357 |
| Long-term debt | 545 | 295 | 256 | 216 | 186 |
| Short-term debt | 1 468 | 1 608 | 2 383 | 1 945 | 1 902 |
| Total debt | 2 013 | 1 904 | 2 639 | 2 161 | 2 088 |
EBITDA margin
2.0%
This company
15.8%
Market median
-87% vs market
20202024
Equity ratio
14.6%
This company
38.2%
Market median
-62% vs market
20202024
Return on equity
43.7%
This company
18.4%
Market median
+138% vs market
20202024
Net profit margin
1.4%
This company
8.1%
Market median
-83% vs market
20202024
Asset turnover
4.61×
This company
1.12×
Market median
+312% vs market
20202024
Debt / equity
5.85×
This company
0.62×
Market median
-844% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
RK Chief Executive Officer | Chief Executive Officer | 2020 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairman | 2018 | |
| Former (1) | ||
| Chairman | 2018 – 2021 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Ringen Apotek Holding As
RINGEN APOTEK KLØFTA AS Board members of RINGEN APOTEK KLØFTA AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Roozbeh Konarboland | Chief Executive Officer | 0 companies |
| Beryll Hanne Kristensen | Chairman | 0 companies |
| Beryll Kristensen Konarboland | Chairman | 0 companies |